Monday, 31 August 2026European Markets

ONWARD MEDICAL Stock 9.13% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with ONWARD MEDICAL (ONWD.BR) rising 9.13% to €5.14 on Friday while BEL 20 jumped 1.02% to €3,698.82.

ONWARD MEDICAL's last close was €4.71, 28.42% under its 52-week high of €6.58.

About ONWARD MEDICAL

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -69.93%.

Moving Average

ONWARD MEDICAL's worth is way higher than its 50-day moving average of €3.53 and way higher than its 200-day moving average of €4.19.

Yearly Top and Bottom Value

ONWARD MEDICAL's stock is valued at €5.14 at 21:32 EST, way under its 52-week high of €6.58 and way higher than its 52-week low of €1.85.

More news about ONWARD MEDICAL (ONWD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com